EA202192488A1 - Антитела против tsg-6 и их применения - Google Patents
Антитела против tsg-6 и их примененияInfo
- Publication number
- EA202192488A1 EA202192488A1 EA202192488A EA202192488A EA202192488A1 EA 202192488 A1 EA202192488 A1 EA 202192488A1 EA 202192488 A EA202192488 A EA 202192488A EA 202192488 A EA202192488 A EA 202192488A EA 202192488 A1 EA202192488 A1 EA 202192488A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- applications
- antibodies against
- tsg
- antibodies
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817152P | 2019-03-12 | 2019-03-12 | |
| PCT/CA2020/050321 WO2020181376A1 (en) | 2019-03-12 | 2020-03-11 | Tsg-6 antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192488A1 true EA202192488A1 (ru) | 2022-02-08 |
Family
ID=72427149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192488A EA202192488A1 (ru) | 2019-03-12 | 2020-03-11 | Антитела против tsg-6 и их применения |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220153834A1 (https=) |
| EP (1) | EP3938389A4 (https=) |
| JP (1) | JP2022522815A (https=) |
| KR (1) | KR20210138674A (https=) |
| CN (1) | CN113748130A (https=) |
| AU (1) | AU2020234533A1 (https=) |
| BR (1) | BR112021017810A2 (https=) |
| CA (1) | CA3129302A1 (https=) |
| EA (1) | EA202192488A1 (https=) |
| IL (1) | IL286216A (https=) |
| MX (1) | MX2021010766A (https=) |
| SG (1) | SG11202109708TA (https=) |
| TW (1) | TW202100551A (https=) |
| WO (1) | WO2020181376A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023192829A2 (en) * | 2022-03-28 | 2023-10-05 | University Of Florida Research Foundation, Incorporated | Alpha-1 antitrypsin z- and m-specific binding proteins |
| TWI876557B (zh) * | 2022-09-30 | 2025-03-11 | 臺北醫學大學 | 用於前列腺癌診斷和早期發病的單株抗體 |
| KR102582500B1 (ko) | 2022-10-27 | 2023-09-26 | 서울대학교산학협력단 | Tnfaip6 -조작된 종양 세포 및 이의 이용 |
| WO2024102759A1 (en) * | 2022-11-07 | 2024-05-16 | Board Of Regents, The University Of Texas System | Methods involving detecting tnf stimulated gene 6 (tsg-6) for improving anti-tumor responses to immune therapy in cancer patients |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896058A1 (en) * | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| AU2015301338C1 (en) * | 2014-08-04 | 2021-07-22 | Baylor Research Institute | Antagonistic anti-OX40L antibodies and methods of their use |
| PT3186281T (pt) * | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
-
2020
- 2020-03-11 US US17/434,368 patent/US20220153834A1/en not_active Abandoned
- 2020-03-11 CA CA3129302A patent/CA3129302A1/en active Pending
- 2020-03-11 JP JP2021551926A patent/JP2022522815A/ja active Pending
- 2020-03-11 KR KR1020217032689A patent/KR20210138674A/ko not_active Ceased
- 2020-03-11 SG SG11202109708T patent/SG11202109708TA/en unknown
- 2020-03-11 AU AU2020234533A patent/AU2020234533A1/en active Pending
- 2020-03-11 MX MX2021010766A patent/MX2021010766A/es unknown
- 2020-03-11 TW TW109108016A patent/TW202100551A/zh unknown
- 2020-03-11 WO PCT/CA2020/050321 patent/WO2020181376A1/en not_active Ceased
- 2020-03-11 EA EA202192488A patent/EA202192488A1/ru unknown
- 2020-03-11 BR BR112021017810A patent/BR112021017810A2/pt unknown
- 2020-03-11 CN CN202080028139.0A patent/CN113748130A/zh active Pending
- 2020-03-11 EP EP20769649.3A patent/EP3938389A4/en not_active Withdrawn
-
2021
- 2021-09-09 IL IL286216A patent/IL286216A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3129302A1 (en) | 2020-09-17 |
| JP2022522815A (ja) | 2022-04-20 |
| AU2020234533A1 (en) | 2021-09-16 |
| MX2021010766A (es) | 2021-12-10 |
| TW202100551A (zh) | 2021-01-01 |
| SG11202109708TA (en) | 2021-10-28 |
| US20220153834A1 (en) | 2022-05-19 |
| CN113748130A (zh) | 2021-12-03 |
| WO2020181376A1 (en) | 2020-09-17 |
| IL286216A (en) | 2021-10-31 |
| EP3938389A4 (en) | 2022-11-09 |
| BR112021017810A2 (pt) | 2021-11-23 |
| EP3938389A1 (en) | 2022-01-19 |
| KR20210138674A (ko) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EA202090372A1 (ru) | Универсальные соединения авт и их применение | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| MX2021008507A (es) | Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas. | |
| MX2023010661A (es) | Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения | |
| EA202192254A1 (ru) | Fcmr-связывающие молекулы и их применение |